The expression of CD30 detected by IHCseems to be associated with an inferior clinical outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, who may benefit from experimental therapies such as anti-CD30 monoclonal antibody. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.